Peter Beitsch, MD, President at The American Society of Breast Surgeons, Dallas Surgical Group, discusses the impact of pertuzumab on patients with luminal subtype breast cancer.
Peter Beitsch, MD
Advertisement
Articles by Peter Beitsch, MD
Advertisement
Latest Updated Articles
Dr. Peter Beitsch on Pertuzumab in Luminal Subtype Breast CancerPublished: January 18th 2016 | Updated:
Advertisement
Advertisement
Trending on OncLive
1
FDA Accepts BLA for Ivonescimab Plus Chemotherapy in EGFR-Mutant NSCLC After TKI Progression
2
FDA Approval Sought for Lirafugratinib in Second-Line, FGFR2-Altered Cholangiocarcinoma
3
2025 Data Across Gynecologic, Lung, and Hematologic Cancers Reshape Treatment Landscapes
4
Third NDA for Rivoceranib/Camrelizumab Is Resubmitted to FDA for Unresectable HCC
5